Everything below concerns tirzepatide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-20. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
=== Diagnostic tests === Once monoclonal antibodies for a given substance have been produced, they can be used to detect the presence of this substance. Proteins can be detected using the Western blot and immuno dot blot tests. In immunohistochemistry, monoclonal antibodies can be used to detect antigens in fixed tissue sections, and similarly, immunofluorescence can be used to detect a substance in either frozen tissue section or live cells.
== History == In 1916, Bennett M. Allen and Philip E. Smith found that the pituitary contained a thyrotropic substance. The first standardised purification protocol for this thyrotropic hormone was described by Charles George Lambie and Victor Trikojus, working at the University of Sydney in 1937.
=== Drug manufacturing === Due to the environmental factors present in outer space, alternative manufacturing methods are explored to produce medicines for astronaut use. For example, measuring the weight and volume of medicine ingredients in microgravity conditions is difficult and requires zero-gravity mass measurement devices. Current manufacturing methods also rely heavily on large and heavy machining, which cannot fit on spacecraft due to constrained spaces. New manufacturing methods for medicines have been developed that can adapt to outer space's environmental constraints. Chemputing is a chemical-robot system that uses limited technology to synthesize raw materials for pharmaceuticals. This apparatus includes a reaction flask, a jacketed filtration setup, an automated liquid-liquid separation module, and a solvent evaporation module, allowing astronauts to develop compounds on demand, not requiring a large space and taking into account the constraints of spaceflight. Additive manufacturing has already been used on Earth in the personalized medicine field and there are methods sent to outer space for drug manufacturing and fabrication.
Polystyrene Composition – The University of Southern Mississippi SPI resin identification code – Society of the Plastics Industry Polystyrene: Local Ordinances – Californians Against Waste Take a Closer Look at Today's Polystyrene Packaging (brochure by the industry group American Chemistry Council, arguing that the material is "safe, affordable and environmentally responsible") Lettieri TR, Hartman AW, Hembree GG, Marx E (1991). "Certification of SRM1960: Nominal 10 μm Diameter Polystyrene Spheres ("Space Beads")". Journal of Research of the National Institute of Standards and Technology. 96 (6): 669–691. doi:10.6028/jres.096.044. PMC 4915770. PMID 28184141.
== Treatment == Emerging therapies for genetic skeletal dysplasias include enzyme replacement therapy, small molecule therapy, hematopoietic stem cell transplantation and gene therapy. These therapies aim at preventing disease progression and thus improving quality of life. Enzyme replacement therapies are some of the mucopolysaccharidoses and Gaucher disease. Results have shown effectivity of enzyme replacement therapy. Hematopoietic stem cell transplantation can be lifesaving for some disorders, such as with malignant infantile osteopetrosis. Even with treatments such as enzyme replacement therapy and stem cell transplantation, people with skeletal dysplasia often require orthopedic surgery and other disease management interventions. There is a lack of information available to support these patients as most physicians may only see one or two skeletal dysplasia patients in their lifetime. Guidelines are available to support best practices for managing several areas of skeletal dysplasia, such as the craniofacial aspects of skeletal dysplasia, spinal disorders, diagnosis and management of type II collagen disorders, pregnancy of people with skeletal dysplasia, peri-operative management, and foramen magnum stenosis in achondroplasia. Written and video resources for patients with skeletal dysplasia and caregivers are also available.
Sources: en.wikipedia.org
As a result, it is often combined with these drugs to reduce their side-effect profile and to produce a stronger antidepressant effect. Mirtazapine does not have pro-serotonergic activity and thus does not cause serotonin syndrome. This is in accordance with the fact that it is not a serotonin reuptake inhibitor or monoamine oxidase inhibitor, nor a serotonin receptor agonist. There are no reports of serotonin syndrome in association with mirtazapine alone, and mirtazapine has not been found to cause serotonin syndrome in overdose. However, there are a handful of case reports of serotonin syndrome occurring with mirtazapine in combination with serotonergic drugs like selective serotonin reuptake inhibitors, although such reports are very rare, and do not necessarily implicate mirtazapine as causative.
This so-called reconciliation bill is in fact a big retaliation bill—retaliation against AFGE and other unions for successfully standing up for our members and fighting this administration's illegal attempts to obliterate our federal agencies and the patriotic civil servants who run our federal programs. These provisions represent a direct assault on federal employees and their labor unions and will make it that much harder for federal agencies to recruit and retain the qualified employees they desperately need to serve the American public. The 2001 recipient of the Nobel Memorial Prize in Economic Sciences, Joseph Stiglitz, was asked about the OBBBA in an interview with Swiss Radio and Television (SRF) as to how he would describe the legislation, to which he had replied:
Instances of users abusing software to generate controversial statements in the vocal style of celebrities, public officials, and other famous individuals have raised ethical concerns over voice generation AI. In response, companies such as ElevenLabs have stated that they would work on mitigating potential abuse through safeguards and identity verification. Concerns and fandoms have spawned from AI-generated music. The same software used to clone voices has been used on famous musicians' voices to create songs that mimic their voices, gaining both tremendous popularity and criticism. Similar techniques have also been used to create improved quality or full-length versions of songs that have been leaked or have yet to be released.
"Controversy surrounds both the drug study itself and the FDA approval," wrote NEJM editor-at-large Richard P. Wenzel, MD in 2002. The FDA approved the drug despite the advisory committee's split vote (10 to 10) due to concerns about the validity of the claimed efficacy and safety findings on the basis of a single trial. Eli Lilly spokeswoman Judy Kay Moore insisted that the company did not mastermind the ethics task force or steer the guideline-writing process. It was only a coincidence, Moore says, that the ethics task force and the Surviving Sepsis Campaign used the same P.R. firm, Belsito and Company.
Sources: en.wikipedia.org
== Personal life == Kiggans is a lifelong Roman Catholic. She has been married since 1999 to Steve Kiggans, a retired Navy F-18 pilot. They have four children. Kiggans' father is also a veteran, serving in the Vietnam War as an Army Green Beret.
Pyridines are a class of chemical substances that comprise a pyridine ring. The pyridine structure, which appears as a substructure in the of this class members, is an aromatic six-membered ring containing a nitrogen atom. Pyridines belong to the heterocycles. Pyridine rings are clearly aromatics and in many respects behave similarly to aromatic hydrocarbons. On the other hand, the presence of the nitrogen atom also leads to differences between pyridines and benzenoid aromatics; for example, pyridines react basically. Pyridines have been known since the 19th century. A particularly important figure in pyridine research was Alexei Yevgenyevich Chichibabin. The Chichibabin pyridine synthesis named after him, as well as many other pyridine syntheses, are based on the condensation of various carbonyl compounds with ammonia. Pyridines play an essential role in living organisms, as vitamin B3 and vitamin B6 are based on a pyridine structure. Pyridine rings are also components of many alkaloids of animals and plants, including nicotine and other tobacco alkaloids. Pyridines are also of great importance in industry and research. The parent compound pyridine is used annually on a million-ton scale. Pyridine and its derivatives are used as solvents, bases, catalysts, complex ligands, and intermediates in the production of other compounds. The pyridine ring is a common and important structural element in pharmaceuticals.
Classical (or "Werner Complexes"): Ligands in classical coordination chemistry bind to metals, almost exclusively, via their lone pairs of electrons residing on the main-group atoms of the ligand. Typical ligands are H2O, NH3, Cl−, CN−, en. Some of the simplest members of such complexes are described in metal aquo complexes, metal ammine complexes, Examples: [Co(edta)]−, [Co(NH3)6]3+, [Fe(C2O4)3]3− Organometallic chemistry: Ligands are organic (alkenes, alkynes, alkyls) as well as "organic-like" ligands such as phosphines, hydride, and CO. Example: (C5H5)Fe(CO)2CH3 Bioinorganic chemistry: Ligands are those provided by nature, especially including the side chains of amino acids, and many cofactors such as porphyrins. Example: hemoglobin contains heme, a porphyrin complex of iron Example: chlorophyll contains a porphyrin complex of magnesium Many natural ligands are "classical" especially including water. Cluster chemistry: Ligands include all of the above as well as other metal ions or atoms as well. Example Ru3(CO)12 In some cases there are combinations of different fields: Example: [Fe4S4[S(cysteinyl)]4]2−, in which a cluster is embedded in a biologically active species. Mineralogy, materials science, and solid state chemistry – as they apply to metal ions – are subsets of coordination chemistry in the sense that the metals are surrounded by ligands. In many cases these ligands are oxides or sulfides, but the metals are coordinated nonetheless, and the principles and guidelines discussed below apply. In hydrates, at least some of the ligands are water molecules.
== External links == "BRENDA". Archived from the original on 1 April 2022., Database of enzymes giving lists of known inhibitors for each entry "PubChem". National Center for Biotechnology Information. National Library of Medicine. Database of drugs and enzyme inhibitors "Symbolism and Terminology in Enzyme Kinetics". Archived from the original on 20 June 2006. Recommendations of the Nomenclature Committee of the International Union of Biochemistry (NC-IUB) on enzyme inhibition terminology
Elam came under the domination of Akkad in the time of Sargon though it remained restive. The 2nd ruler of Akkad, Rimush, campaigned there afterward adding "conqueror of Elam and Parahsum" to his royal titulary. The 3rd ruler, Manishtushu, conquered the city of Anshan in Elam and also the city of Pashime, installing imperial governors in those places. Naram-Sin added "commander of all the land of Elam, as far as Parahsum," to his royal titulary. During his rule, "military governors of the country of Elam" (shakkanakkus) with typically Akkadian names are known, such as Ili-ishmani or Epirmupi. This suggests that these governors of Elam were officials of the Akkadian Empire. Naram-Sin exercised great influence over Susa during his reign, building temples and establishing inscriptions in his name, and having the Akkadian language replace Elamite in official documents.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.